Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Stanford University

Status: Completed

Conditions: Lymphomas: Non-Hodgkin Marginal Zone; Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia; Lymphomas: Non-Hodgkin Cutaneous Lymphoma; Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell; Lymphomas: Non-Hodgkin Diffuse Large B-Cell; Lymphomas: Non-Hodgkin; Lymphoma, Non-Hodgkin; Lymphomas: Non-Hodgkin Peripheral T-Cell; Lymphomas: Non-Hodgkin Mantle Cell

Treatments: Drug: Rituximab; Drug: Epratuzumab

Study type: Interventional

Funder types: Other; Industry; NIH

Identifiers

NCT00398372

77550

LYMNHL0031

CA09287

200114861

NCT00398372

CA111827

Details and patient eligibility

About

To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment